Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

2.040 +0.070 (+3.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,900,926
Open 1.990
Bid (Size) 2.020 (14)
Ask (Size) 2.060 (35)
Prev. Close 1.970
Today's Range 1.940 - 2.120
52wk Range 0.7000 - 3.400
Shares Outstanding 28,277,493
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Esperion to Participate in Upcoming May Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report First Quarter 2024 Financial Results on May 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-30.14%
-30.14%
1 Month
-26.88%
-26.88%
3 Month
+0.99%
+0.99%
6 Month
+146.14%
+146.14%
1 Year
+43.66%
+43.66%

More News

Read More
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Earnings Scheduled For February 27, 2024
Via Benzinga
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Preview: Esperion Therapeutics
Via Benzinga
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Exposures Glyphosate
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Why Is Heart Disease-Focused Esperion Therapeutics Stock Trading Higher On Monday?
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Esperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
From Esperion Therapeutics
Via Business Wire
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
From Esperion Therapeutics, Inc.
Via GlobeNewswire
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.